Voellmy Richard, Bloom David C, Vilaboa Nuria, Feller Joyce
HSF Pharmaceuticals SA, La Tour-de-Peilz, Switzerland.
Department of Physiological Sciences, University of Florida College of Veterinary Sciences, Gainesville, Florida, USA.
Methods Mol Biol. 2017;1581:55-78. doi: 10.1007/978-1-4939-6869-5_4.
Herpes simplex virus (HSV) causes significant morbidity on the human population through such clinical syndromes as cold sores, genital herpes, herpes stromal keratitis, and encephalitis. Attempts to generate efficacious vaccines to date have failed. We have recently described the use of a conditionally replication-competent HSV-1 vector to immunize mice against a lethal challenge of HSV-1. The unique feature of this vaccine vector is that its replication is tightly controlled and can only occur in the presence of local heat and the presence of a small molecule inducer (an antiprogestin). This gives it the safety advantage of a replication-defective vaccine vector as well as the advantage of a replication-competent vector in that it is able to stimulate innate and adaptive aspects of the immune response in a natural context that a replication-defective vector cannot. In this chapter we provide a brief overview of HSV vaccines followed by the methodology used to propagate and utilize replication-conditional HSV vectors as vaccines.
单纯疱疹病毒(HSV)通过唇疱疹、生殖器疱疹、疱疹性基质角膜炎和脑炎等临床综合征给人类带来了巨大的发病率。迄今为止,研发有效疫苗的尝试均以失败告终。我们最近描述了使用一种具有条件复制能力的HSV - 1载体来免疫小鼠,使其免受HSV - 1的致死性攻击。这种疫苗载体的独特之处在于其复制受到严格控制,只有在局部加热和小分子诱导剂(一种抗孕激素)存在的情况下才能发生。这赋予了它复制缺陷型疫苗载体的安全优势,以及复制能力型载体的优势,即它能够在自然环境中刺激免疫反应的先天和适应性方面,而复制缺陷型载体则无法做到。在本章中,我们首先简要概述HSV疫苗,然后介绍用于繁殖和利用复制条件性HSV载体作为疫苗的方法。